Osteoporosis - Drug Pipeline Analysis and Market Forecasts t - PowerPoint PPT Presentation

rgunnam
osteoporosis drug pipeline analysis and market forecasts to 2016 l.
Skip this Video
Loading SlideShow in 5 Seconds..
Osteoporosis - Drug Pipeline Analysis and Market Forecasts t PowerPoint Presentation
Download Presentation
Osteoporosis - Drug Pipeline Analysis and Market Forecasts t

play fullscreen
1 / 4
Download Presentation
Osteoporosis - Drug Pipeline Analysis and Market Forecasts t
676 Views
Download Presentation

Osteoporosis - Drug Pipeline Analysis and Market Forecasts t

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Osteoporosis - Drug Pipeline Analysis and Market Forecasts to 2016

  2. The Osteoporosis Therapeutics Market is Forecast to Show Significant Growth to 2016 The global osteoporosis therapeutics market was valued at $9.6 billion in 2009. It is expected to grow to $16.7 billion at a compound annual growth rate (CAGR) of 8.2% by 2016. This significant growth is primarily attributed to strong current treatment options as well as strong pipeline candidates. The increase in the prevalence of osteoporosis among the female population is the principal driver of the osteoporosis market and will continue to be in the future. The significant reason for the increase in prevalence is due to the decline in the use of hormone replacement therapy (HRT) in healthy postmenopausal women. HRT has been used to help prevent the bone loss that leads to osteoporosis. However, recent negative study results, showing the increased risk of heart attack, stroke, breast cancer and blood clots, have led to a decline in HRT usage. Therefore, population growth and the increase in the prevalent population will combine to contribute to the increased burden of osteoporosis. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Osteoporosis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare Current Treatment Options are Moderately Successful in Meeting Market Demand GlobalData has analyzed the current market landscape and found it to be strong. Antiresorptive and bone-forming drugs are the two main types of drugs which are used in the treatment of osteoporosis. Bisphosphonates, calcitonin, estrogen and estrogen agonists/antagonists are the major antiresorptive drugs available in the market. They include alendronate (Fosamax), risedronate (Actonel), ibandronate (Bonivia), zoledronic acid (Reclast) and raloxifene (Evista). The market is currently dominated by antiresorptive drugs. However, bone-building drugs are being developed by researchers and are just becoming available. Eli Lilly is the only company which has two products – Evista and Forteo in the osteoporosis market. Neither of these drugs are part of the bisphosphonate class. Forteo is the first and the only bone-forming drug available in the market.

  3. Poor Diagnosis of the Disease is a Major Barrier for the Osteoporosis Market The poor diagnosis of the disease is a major barrier for the osteoporosis market. One of the major reasons why osteoporosis is underdiagnosed is that most vertebral fractures are asymptomatic and therefore go unrecognized by the patient and physician. Even patients with clinically apparent fragility fractures are overlooked, with fewer than 5% of patients with osteoporotic fractures being referred for medical evaluation and treatment. The large majority of patients with fragility fractures are not referred for further evaluation and treatment. Studies have shown that older women and men with hip fractures do not receive follow-up drug treatment. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Osteoporosis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare Strong Pipeline Candidates are Expected to Intensify Future Competition GlobalData found that there are more than 130 products in different stages of development. Most of the products in clinical development are me-too. These products are a mixture of calcium modulators, cathepsin K (CTSK) inhibitor, bone-tissue resorption inhibitors and selective estrogen receptors modulators (SERM). If successfully launched, these products are expected to meet patients’ expectations. It may also lead to an intensely competitive market landscape and the existing market leaders will have to be prepared to manage this dynamic, yet challenging, scenario. The largest growth driver of the osteoporosis market is expected to be Amgen’s Prolia (denosumab), which is the first monoclonal antibody on the market.

  4. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Osteoporosis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare Or visit our report store: http://www.globaldata.com/reportstore Contact Information: Rajesh Gunnam rgunnam@globaldata.com +914066166782